Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Net Margin (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Net Margin data on record, last reported at 3.85% in Q4 2025.

  • For Q4 2025, Net Margin rose 2008.0% year-over-year to 3.85%; the TTM value through Dec 2025 reached 4.48%, up 2162.0%, while the annual FY2025 figure was 4.48%, 2162.0% up from the prior year.
  • Net Margin reached 3.85% in Q4 2025 per MIRM's latest filing, down from 2.18% in the prior quarter.
  • Across five years, Net Margin topped out at 1825.37% in Q4 2021 and bottomed at 942.16% in Q3 2021.
  • Average Net Margin over 5 years is 41.85%, with a median of 49.42% recorded in 2023.
  • The widest YoY moves for Net Margin: up 75203bps in 2022, down -195592bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1825.37% in 2021, then plummeted by -107bps to 130.55% in 2022, then surged by 61bps to 51.27% in 2023, then soared by 53bps to 23.93% in 2024, then skyrocketed by 84bps to 3.85% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 3.85% in Q4 2025, 2.18% in Q3 2025, and 4.59% in Q2 2025.